However, the characteristic of TRAIL resistance has been observed in some of the NSCLC cell lines, indicating that not all the NSCLC subtypes would benefit from MSC-TRAIL treatment [51,52]. This evidence concerns the gene TNFSF10 and non-small cell lung carcinoma.